Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fenugreek seeds tested as a natural remedy for metabolic syndrome

NCT ID NCT07056712

Disease control Sponsor: University of Guadalajara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether taking fenugreek seed powder daily for 12 weeks can improve key signs of metabolic syndrome, such as waist size, blood pressure, cholesterol, and blood sugar. Researchers will compare fenugreek to a placebo in 28 adults aged 30 to 60 who have metabolic syndrome. The goal is to see if this common spice can help control the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fenugreek seed
What this could lead to
If it works, this could point toward a natural supplement to help manage metabolic syndrome.
What could go wrong
This is a small, early-stage trial with only 28 people, so results may not apply widely. Fenugreek may cause digestive upset or interact with medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women between 30 and 60 years old. * Diagnosis of Metabolic Syndrome (MS) according to the International Diabetes Federation (IDF) criteria. Waist circumference ≥90 cm in men and ≥80 cm in women, plus the presence of two or more of the following criteria: * Fasting glucose ≥100 mg/dL or previous diagnosis of type 2 diabetes. * Systolic Blood Pressure ≥130 mmHg. * Diastolic Blood Pressure ≥85 mmHg. * Triglycerides ≥150 mg/dL. * HDL cholesterol \<40 mg/dL in men and \<50 mg/dL in women. * Body Mass Index between 25.0 and 34.9 kg/m². * Stable weight during the 3 months prior to the start of the study (weight variation less than 10%). * Not receiving pharmacological treatment for any component of MS, insulin sensitivity, and/or insulin secretion. * Signed informed consent form. Non-Inclusion Criteria: * Suspected or confirmed pregnancy. * Breastfeeding period. * Fasting glucose ≥126 mg/dL. * LDL cholesterol ≥155 mg/dL. * Triglycerides ≥500 mg/dL. * Systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg. * Use of medications and/or supplements known to influence the study variables. * History of kidney, thyroid, liver disease, or ischemic heart disease. * Active smoker. * Not using an effective and stable contraceptive method. Exclusion Criteria: * Voluntary withdrawal of informed consent. * Treatment adherence ≤80%. * Occurrence of a serious adverse event. * Loss to follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Insulin Resistance metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto de Terapéutica Experimental y Clínica (INTEC), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara.

    Guadalajara, Jalisco, 44340, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.